through specific membrane receptors coupled with G-proteins (PAF-receptor) (6, 14) .
Two different and distinct enzymatic routes of PAF biosynthesis have been reported, namely the de novo and the remodeling pathways, with PAF-Cholinephosphotransferase (PAF-CPT, EC 2.7.8. 16) and Lyso-PAF-Acetyltransferase (Lyso-PAF-AT, EC 2.3.1.67) being their key regulatory enzymes (lS-17) . The main enzyme involved in the catabolism of PAF in plasma is a PAF-specific Acetylhydrolase (PAF-AH, EC 3.1.1.47) (18) , also known as Lipoprotein-associated phospholipase A, (Lp-PLA,). Dysregulation ofPAF metabolism alters"the levels~f PAF with implications in the onset and progression of several pathological conditions (6) (7) (8) (9) (10) (11) (12) (13) (14) .
A great variety of PAF-antagonists, including ginkgolides, have been studied in various pathological conditions, including HIV-related disorders, with promising results (9) (10) (11) (12) (13) (19) (20) .
Our group previously described that several, specific or not, PAF inhibitors affect also the activities of its basic metabolic enzymes (l3, [21] [22] .
In the present pilot study, PAF metabolism in two of our HIV infected patients who received a Ginkgo hi/aha extract as food supplement was investigated. The specific activities of PAF key biosynthetic enzymes, in blood samples of these patients, before and during the use of Ginkgo biloba for a period of 9 months, were studied.
MATERIALS AND METHODS

Materials and instruments
Centrifugations were performed in a Heraeus Labofug 3L-R, a Heraeus Labofug 400R (Heraeus Hanau, Germany) and a Sorvall RC-5B refrigerated ultracentrifuge (DuPont de Nemours & Co., Inc .. Sorvall Instruments Div., Newtown. CT) apart from the centrifugation at 20,000xg, which was performed in a refrigerated Micro 22R Zentri fugen Hettich ultracentrifuge (Hettich, Kirchlengern, East Westphalia, Germany). Homogenizations were conducted in 30% of the power of a supersonic Bandelin Sonoplus HD 2070 sonicator (Bandel in. Berlin. Germany). The liquid scintillation counter used was a 1209 Rackbeta (Pharmacia, Wallac, Finland). PAF-induced platelet aggregation studies were performed in a model 400 VS aggregometer of Chronolog (Havertown, PA, USA) coupled to a Chrono-log recorder at 37°C with constant stirring at 1200 rpm.
BSA (bovine serum albumin), PAF (I-O-hexadeeyl-2- 
Measurement of CD4 cell counts, viral load and biochemical markers in blood ofHlv-infected patients
Absolute CD4 cell counts were automatically calculated using Tetra One System on the EPICS XL flow cytometer (Beckman Coulter, Inc., Brea, CA USA), while viral load was determined using the Versant HIV-I RNA 3.0 assay (bONA). The kit for this assay was purchased by Siemens (Siemens Healthcare Diagnostics, Tarytown, NY, USA).
Biochemical parameters were measured using appropriate methods in a Siemens Dimension Rxl automatic analyzer (Siemens Center, 60 MacPherson Road, Singapore 348615).
Patients
In July 2007, we were informed by two of our asymptomatic, male, Hlv-infected patients of their intention to start receiving a Ginkgo biloba extract as food supplement. On this occasion, we obtained their approval to evaluate PAF metabolism before and during the intake of Ginkgo biloba, as part of their regular follow-up. The first one was a treatment-naive patient with known seroconversion date, while the second one was HAART experienced even though out of treatment since June 2003.
Neither of them had diabetes, renal failure, nephritic syndrome, active hepatitis, cirrhosis or concurrent infections or took medication for treatment of hyperlipidemia during the study period. The patients received the same Ginkgo biloba leaf extract (Quest vitamins, Aston Science Park, Birmingham, UK) at a dosage of 150 mg once daily providing 36 mg of Ginkgo Flavonglycosides, 4.5 mg of Ginkgolides A,B and C and 3.8 mg of Bilobalide. Blood samples were collected just before (baseline time, defined as 0 months) and after 1,3, 6 and 9 months of Ginkgo use.
Isolation ofplasma, leukocytes, platelets and red blood cells from blood ofHiVsinfected patients
The isolation of plasma, leukocytes and platelets from blood samples of these patients was performed as previously described (13, 22) with some modifications. Briefly, 9 mL blood was obtained from each naive patient (after a IO-hour overnight fast) in I mL of an anticoagulant solution of sodium citrate / citrate acid. The sample was centrifuged at 194xg for 10 min at 25°C (I st centrifugation). Then four simultaneous procedures were carried out: a) Isolation ofplasma The supernatant of the I st centrifugation (plasma rich in platelets) was centrifuged at 1400xg for 20 min at 25°C (2 ml centrifugation).
The supernatant of the 2 nd centrifugation (plasma) was further centrifuged at 20,000xg for Ih at 4°C (3 rd centrifugation), in order to remove the viral load. This supernatant (plasma) was aliquoted and stored at -80°C until the time of the PAF-AH assay analysis.
b) Isolation ofhuman platelets (HPs)
The pellet of the 2nd centrifugation (platelets) was re-suspended in saline and further centrifuged at 1400xg for 20 min at 25°C (4 th centrifugation) in order to remove contaminating plasma remains. The pellet of this centrifugation (platelets) was re-suspended in I mL of a buffer containing 50 mM Tris-HCI (pH 7.4) and sonicated on ice at 40 KHz (indicated as 30% of the total potential of this sonicator) (4x 15 s). Then it was further centrifuged at 500xg for 10 min at 4°C (5 th centrifugation), in order to remove whole cells, nuclei and debris in the pellet, while the supernatants (platelets homogenates) after protein determination were aliquoted and stored at -80°C until the time of the PAF-CPT and Lyso-PAF-AT assay analyses. c)
Isolation ofhuman leukocytes (HLs)
In the pellet of the I st centrifugation (leukocytes and erythrocytes) saline was added until the solution reached the initial volume of 10 mL and after mild shaking was separated in two aliquots of 5 mL each. In each aliquot the isolation of the leukocytes from the contaminating erythrocytes was achieved by erythrocyte sedimentation. 1.7 mL of dextran solution (3% dextran in NaCI 0.15 M) was added in each aliquot and the mixtures were kept for I h at room temperature. The leukocyte-rich supernatants of the two aliquots were united and centrifuged at 500xg for 10 min at room temperature (6 th centrifugation). The supernatant was removed and contaminating erythrocytes of the sediment pellet were lysed with the addition of 5 mL of a lysis solution consisting of ISS mM NH 4CI, 10 mM KHC0 3 , and 0.1 mM EDTA and then removed with a centrifugation at 300xg for 10 min at room temperature (7th centrifugation). The pelleted cells of the 7th centrifugation (isolated leukocytes) were re-suspended in I mL of a buffer containing 50 mM Tris-HCI (pH 7.4) and sonicated on ice at 40 KHz (indicated as 30% of the total potential of this sonicator) (4x15 s). Then they were centrifuged at 500xg for 10 min at 4°C (8th centrifugation), in order to remove whole cells, nuclei and debris in the pellet, while the supernatants (leukocytes homogenates) after protein determination were aliquoted and stored at -80°C until the time of the PAF-CPT and Lyso-PAF-AT assay analyses. Protein concentrations, determined according to the method of Bradford (23) , were based on BSA as the protein standard.
Enzymatic assays D'Fl-insensitive PAF-CholinephQ.\photranslerase (PAF-CPT) activity assays
The assay was performed three times on the homogenates of HLs and HPs isolated from blood samples collected just before (0 months) and after I, 3, 6 and 9 months of Ginkgo use, as previously described (13, 21, 22) . Briefly, the reaction was carried out at 37°C for 20 min in a final volume of 200 ul. containing 100 mM Tris-HCl (pH 8.0), 15 mM dithiothreitol (DTT), 0.5 mM EDTA, 20 mM MgCI2, Img/mL BSA, 100~lM CDP-Choline, 100 flM I-O-alkyl-2-sn-acetyl-glycerol (AAG, added in the assay mixture in ethanol), and the sample (0.05 mg/mL final concentration of protein). The mixture of Tris, DTT, EDTA, MgCl2 and BSA was incubated at 37°C for 5 min. The sample was initially added to the mixture just before AAG, and after a very short period (15-30 s) of incubation the reaction was started by the addition ofCDP-Choline and was stopped after 20 min by adding 0.5 mL of cold methanol (2% in acetic acid).
Lyso-PAF-AT activity assays
The assay was performed three times on the homogenates of HLs and HPs isolated from blood samples collected just before (0 months) and after 1,3, 6 and 9 months of Ginkgo use, as previously described (13, 22) . Briefly, the reaction was carried out at 37°C for 30 min in a final volume of 200 ul. containing 50 mM Tris-HCI (pH 7,4), 0.25 mg/mL BSA, 20 flM Lyso-PAF and 200 flM acetyl-CoA and the sample (0.125 mg/mL final concentration of protein). The reaction was started by adding the homogenate sample and was stopped after 30 min by adding 2% acetic acid methanol.
Determination of PAF-bi05ynthetic enzymes (PAF-CPT and Lyso-PAF-AT) activities
The extraction, purification and determination ofPAF produced in each assay were carried out as previously described (13, (21) (22) . Briefly, PAF was extracted according to the Bligh-Dyer method (24) and was separated by thin-layer chromatography (TLC) on Silica Gel G coated plates with an elution system consisting of chloroform: methanol: acetic acid: water (100:57: 16:8, vi v/v/v). PAF fractions were scraped off and extracted, (24) and the amount of produced PAF was determined by the washed rabbit platelet aggregation assay (7) .
All assays were performed in duplicate in each of the three sample homogenates of either HLs or HPs from each patient (n = 2x3 = 6 values for each enzyme activity per homogenate per patient). Specific enzymatic activities of PAF-CPT and Lyso-PAF-AT were expressed as pmol of produced PAF/min/mg of protein present in each assay.
Lp-PLA 2 activity assays
Lp-PLA 2 was determined by the trichloroacetic acid precipitation method using PH] PAF as a substrate, as previously described (25) . Assay was performed on plasma isolated from blood samples collected just before (0 months) and after I, 3, 6 and 9 months of ginkgo use. Briefly, 2 ul. of plasma were incubated with 4 nmol of [lH]-PAF (20 Bq per nmol) for 30 min at 37°C in a final volume of 200 ul. of 50 mM Tris/HCl buffer (pH 7.4). The reaction was terminated by the addition of cold trichloroacetic acid (10% final concentration). Then, the samples were placed in an ice bath for 30 min and subsequently centrifuged at 16000xg for 5 min. The [3H]_ acetate released into the aqueous phase was measured on a liquid scintillation counter. All assays were performed in duplicate in each of the three plasma samples from each patient (n = 2x3 = 6 values for this enzyme activity per plasma sample per patient). The enzyme activity of Lp-PLA 2 was expressed as nmol ofPAF degraded per min per mL of plasma present in each assay.
Statistical analysis
Normal distribution of variables was checked using Kolmogorov-Smirnov criterion before further analysis. Differences in enzymatic specific activities of the same enzyme during Gingko use were .conducted using Repeated Measures ANOYA criterion, while differences between PAF-CPT and Lyso-PAF-AT enzymatic specific activities at a particular time were conducted using t-test criterion. In both cases any difference observed was considered to be statistically significant when p value was found below 0.05. Data were analyzed using a statistical software package, SPSS 18.0, and Microsoft Excel 2007 for Windows.
RESULTS
Patients' baseline characteristics, viral load
and CD4 cell count at 0, 1, 3, 6 and 9 months of Ginkgo biloba intake are shown in Tables I and II. Both patients remained clinically stable with no significant laboratory abnormalities regarding their renal, hepatic and lipid profiles during the study period.
At baseline, patient 2 had significantly higher levels of viral load and a lower CD4 cell count compared to patient I. A viral load increase of 0.5 log., was noted at 3 months of Ginkgo biloba intake in patient 1 with a return to baseline value thereafter. A decrease in CD4 cell count was observed after the first month of Ginkgo biloba intake although CD4 levels were consistently above 500cellshll. A viral load increase of 0.7 log., was noted at 9 months in patient 2 with a CD4 cell count of 367 cells/ul. PAF metabolism in blood cells and plasma from patient 1 is illustrated in Fig. 1 (a-e ). Concerning the de novo pathway, the mean value of PAF-CPT specific activity in HLs was doubled after the first month of Ginkgo biloba use compared to its baseline activity, while it returned to its baseline levels thereafter (Fig. la) .
PAF-CPT-specific activity of HPs started to decline from the first month of Ginkgo biloba use and it progressively decreased during the study period, reaching statistical significance from the 3 rd month (p< 0.05). This reduction was more pronounced at 9 months of Ginkgo biloba use with a decline of 53 ± 12% compared to baseline PAF-CPT activity (p<0.05) (Fig. 1b) .
Concerning the remodeling pathway, the mean value of Lyso-PAF-AT specific activity in HLs was significantly higher at 3 months compared to its baseline levels, while it decreased thereafter, returning to its baseline levels at 9 months (Fig.  lc) . Lyso-PAF-AT activity of HPs in this patient remained relatively stable during Ginkgo biloba use (Fig. l d) .
Regarding PAF degradation, Lp-PLA 2 specific activity also remained relatively stable (Fig. 1e) .
PAF metabolism in blood cells and plasma from patient 2 is illustrated in Fig. 2 (a-e ). Concerning the de novo pathway, an increase of PAF-CPT specific activity in HLs was observed from the first month and it was sustained until 9 months of Ginkgo biloba use (p< 0.05). This increase was more pronounced at 3 and 9 months when the enzyme activity was doubled compared to baseline ( p<0.05) ( Fig. 2a ). On the contrary, a decline in PAF-CPT specific activity of HPs was observed from the first month with a statistically significant reduction of 65 ± 14% compared to baseline (p<0.05) at 6 and 9 months of Ginkgo biloba use (Fig. 2b) .
Concerning the remodeling pathway, Lyso-PAF-AT-specific activity in HLs was significantly increased during the study period. This enzymatic activity was doubled from the first month, with a peak observed at 6 months (p<0.05) when a 10-fold increase compared to baseline was noted. (Fig. 2c) . On the other hand, the mean value of Lyso-PAF-ATspecific activity in HPs remained relatively stable (Fig.2d) .
Regarding PAF degradation, a statistically significant increase of 30 ± 9% compared to baseline (p<0.05) in Lp-PLA 2 specific activity was observed at the first month of Ginkgo biloba use. However, Lp-PLA 2 specific activity returned to its baseline levels at 3 months and subsequently remained relatively stable ( Fig. 2e ).
DISCUSSION
To our knowledge, this is the first time that the in vivo effects of a standardized formulation of Ginkgo biloba extract on PAF metabolism have been studied in blood cells and plasma of HIV-infected patients.
No other experiments on humans, treated with ginkgolides or Ginkgo biloba extracts, concerning all the basic PAF metabolic enzymes from de novo, remodeling and degradation pathways have been reported to date.
Our previous studies demonstrated that increased PAF biosynthesis is present in the blood of HIVinfected patients, compared to healthy controls, with a profound increase observed in patients with the higher viral load levels (26) . The resulting increased PAF activity in blood seems to be implicated in the progression of HIV infection (19) (20) 26) and in the pathogenesis of several AIDS manifestations (9) (10) (11) (12) (13) .
Our patients received a recommended daily dosage of a standardized Ginkgo biloba extract (150 (19, 20, 27 -28) , one may assume that the above-mentioned inhibition of viral load increment observed at 6 and 9 months of Gingko use was probably related to an effect of Ginkg o use on both PAF metabolism and activities .
Concerning PAF metabolism, this patient experi enced a transient increas e in PAF-CPT specific activity in HLs only at the first month followed by a peak in Lyso-PAF-AT activity at 3 months , coupled with a peak in HIV viral load. The decrease of PAF-CPT activity in HLs to its baseline levels, from the y d month , seems to be related to the subsequent fall of viral load at 6 month s, resulting, in turn, in a simultaneous reduction of Lyso-PAF-AT activity. PAF biosynthesis in HPs was reduced as early as the first month of treatm ent, while no modification of PAF degradation was noted consistent with the low levels of both viral load and PAF biosynthesis.
On the contrary, the HAART-experienced patient with late but not advanced HIV infection (patient 2) developed an increased enzymatic activity of both de novo and remodeling PAF biosynthesis in HLs, following the observed induction in viral replication. This finding is consistent with previous observations relating high viral load levels to Lyso-PAF-AT activity in HLs (13, 26, 28) . A rise in viral load at 9 months with a significant reduction of CD4 cell count caused the immediate initiation of HAART and the discontinuation of Ginkgo bi/oba intake in this patient.
However, PAF biosynthesis in HPs was decreased also in the 2 nd patient, implying that the use of Gingko bi/oba seems to be more effective in HPs than HLs, independently of the baseline heterogeneity of these patients.
Lp-PLA 2 was initially activated in the second patient following, as a host response, the induction of PAF biosynthesis, a result that agrees with previous studies (26, 30) . However, after the first month, a return to baseline was observed despite the sustained viral replication and the subsequent decrement of CD4 cell count.
PAF metabolism as well as the course of HIV infection differed between our patients, probably reflecting their baseline heterogeneity in terms of duration of HIV infection, viral load levels, CD4 cell count and HAART experience. Furthermore, the dosage of Ginkgo bi/oba extract used as food supplement may be insufficient to exert a clinically relevant anti-PAF activity in patients with late HIV infection and high levels of viral replication, as in the 2 nd patient, in contrast to the beneficial anti-PAF effect observed in the Ist patient with early HIV infection and lower viral load levels.
However, regarding the limited number of patients and the lack ofbibliographic evidence, more in vitro and in vivo studies are needed in order to explain the observed alterations of PAF metabolism during different stages of HIV infection and the potential role of PAF antagonists, such as Ginkgo biloba products, in HIV therapeutics.
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